Caution is advised when using MOG in patients undergoing allogeneic hematopoietic cell transplantation, as isolated cases of ATLL and CTCL have indicated an increased likelihood of post-transplant graft-versus-host disease (GVHD) development. This evidence concerns the gene MOG and primary cutaneous T-cell non-Hodgkin lymphoma.